Prostate cancer invasion is promoted by the miR-96-5p-induced NDRG1 deficiency through NF-κB regulation
Invaze karcinomu prostaty je podporována nedostatkem NDRG1 vyvolaným miR-96-5p prostřednictvím regulace NF-κB
Východiska: N-myc downstream-regulovaný gen 1 (NDRG1) má významnou funkci při progresi nádorů. U karcinomu prostaty (prostate cancer – PCa) však regulační mechanizmus NDRG1 zůstává nejasný. Materiál a metody: Hladiny exprese miR-96-5p a NDRG1 byly hodnoceny v buněčných liniích PCa a v tkáních prostaty a validovány ve veřejných databázích pomocí polymerázové řetězové reakce v reálném čase, analýzy western blot a imunohistochemie. Funkce miR-96-5p a NDRG1 byla zkoumána pomocí testů hojení ran a transwell testů in vitro a testu myšího xenoimplantátu in vivo. Dráha regulovaná pomocí NDRG1 byla testována technikou sekvenování nové generace. K detekci vztahu mezi miR-96-5p, NDRG1 a NF-kB dráhou byl použit imunofluorescenční test a test s luciferázou. Výsledky: Nadměrná exprese NDRG1 potlačuje migraci, invazi a epiteliálně-mezenchymální přechod (EMT) in vitro a inhibuje metastázy in vivo. Navíc miR-96-5p přispívá k deficitu NDRG1 a podporuje migraci a invazi buněk PCa. Kromě toho ztráta NDRG1 aktivuje dráhu NF-kB, která stimuluje fosforylaci p65 a IKBa a indukuje EMT v PCa. Závěr: MiR-96-5p podporuje migraci a invazi PCa tím, že cílí na NDRG1 a reguluje dráhu NF-kB.
Klíčová slova:
karcinom prostaty – NDRG1 – miR-96-5p – NF-kB – EMT
Authors:
A. A. Soror 1; R. Eshagh 1; M. R. Fahim 1; A. Jamshidian 2,3; G. H. Monfared 1,3
Authors place of work:
Department of Biology, Faculty of Biological Sciences, East Tehran Branch (Ghiamdasht), Islamic Azad University, Tehran, Iran
1; Tehran Medical Genetics Laboratory, Tehran, Iran
2; Molecular Genetic and Reproductive Biology Department, Kowsar Poly-clinic, Tehran, Iran
3
Published in the journal:
Klin Onkol 2024; 38(2): 95-101
Category:
Přehledy
doi:
https://doi.org/10.48095/ccko202495
Summary
Background: The N-myc downstream-regulated gene 1 (NDRG1) has been discovered as a significant gene in the progression of cancers. However, the regulatory mechanism of NDRG1 remained obscure in prostate cancer (PCa). Methods: The miR-96-5p and NDRG1 expression levels were evaluated in PCa cell lines, and prostate tissues, and validated in public databases by real-time polymerase chain reaction, western blot analysis, and immunohistochemistry. The function of miR-96-5p and NDRG1 were investigated by scratch assay and transwell assays in vitro, and mouse xenograft assay in vivo. The candidate pathway regulated by NDRG1 was conducted by the next-generation gene sequencing technique. Immunofluorescence and luciferase assays were used to detect the relation between miR-96-5p, NDRG1, and NF-kB pathway. Results: Overexpressing NDRG1 suppresses the migration, invasion, and epithelial-mesenchymal transition (EMT) in vitro, and inhibits metastasis in vivo. Moreover, miR-96-5p contributes to NDRG1 deficiency and promotes PCa cell migration and invasion. Furthermore, NDRG1 loss activates the NF-kB pathway, which stimulates p65 and IKBa phosphorylation and induces EMT in PCa. Conclusions: MiR-96-5p promotes the migration and invasion of PCa by targeting NDRG1 and regulating the NF-kB pathway.
Keywords:
prostate cancer – NDRG1 – miR-96-5p – NF- kB – EMT
Introduction
Prostate cancer (PCa) was the second most common malignant tumor in males. Based on the Globocan 2020 estimates of cancer, there were 1,414,259 new cases of PCa worldwide. Moreover, there were also 375,304 patients who died of PCa [1]. Most of the patients were in an advanced stage at the time of the first diagnosis, with lymph nodes or distant metastasis, especially in eastern Asian countries [2]. Although several treatments have been applied recently, the prognosis of PCa remains not well. Therefore, it is necessary to look for reliable biomarkers that play a crucial role in tumor growth and metastasis to distinguish early-stage tumors.
N-myc downstream-regulated gene-1 (NDRG1) is located on chromosome 8q24.3, which contains 16 exons and 15 introns. It is an important member of the NDRG family [3,4]. Epithelial-mesenchymal transition (EMT) is known as a crucial phenotypic conversion. In the process of EMT, cells can change from an epithelial state to a mesenchymal state in a highly plastic and dynamic way, modify the adhesion molecules expressed by cells and make them have migration and invasive behavior [5,6]. Some previous studies have demonstrated that NDRG1 potentially inhibited cancer cell migration, invasion, and EMT by affecting the indispensable molecules involved in metastasis [7,8]. Similar studies suggested that NDRG1 could bind to b-catenin and E-cadherin directly, indicating that these proteins formed a complex. Under the stimulation of WNT3a, ectopic overexpression of NDRG1 maintained b-catenin on the plasma membrane of colon and PCa cells, which blocked the activation of the Wnt pathway [9,10]. In addition, Xi et al. have recently found an effective way to inhibit TNF-a and LYRIC-induced EMT through NDRG1 [11]. NDRG1 also modulated EMT by regulating the level of related protein expression. Elevating E-cadherin and inhibiting vimentin, N-cadherin, slug, and snail-1 have been established by Lee et al. in oral squamous cancer cells [12]. It has also been suggested that NDRG1 potentially attenuates EMT by inhibiting the expression of Smad2 and suppressing the latter-related protein in nasopharyngeal cancer [13]. Though several molecular pathways illustrating the function of NDRG1 have been partially elucidated, the underlying mechanism responsible for NDRG1 and EMT in PCa is still needed further exploration.
MicroRNAs (miRNA) are small endogenous non-coding RNA that binds to a specific sequence of target gene 3 ‘untranslated region (3’UTR) and affects the post-transcriptional regulation of the target gene, which might result in mRNA degradation or translation inhibition [14]. The dysregulation of miRNA in cancer is widely confirmed, and several types of research have shown that the level of miRNA expression was related to tumor metastasis [15,16]. MiR--96 is a member of the miR-183 cluster and has been demonstrated to act as an oncogene or tumor suppressor in tumors [17–21]. Furthermore, recent literature has identified that miR-96 also modulated EMT by regulating the level of related protein expression. Notably, He et al. showed that miR-96 regulated the protein of the EMT-related gene FOXQ1, which could be modulated by TGF‐b1 in bladder cancer [22]. A study by Wang et al. implicated that miR-96-5p promoted proliferation and EMT by directly regulating FOXF2 expression in oral squamous cell carcinoma [23]. Moreover, the circPTPRA and RASSF8 suppressed EMT and metastasis of non-small cell lung carcinomas also by competitive sponging miR-96-5p [24]. MiR-96-5p was markedly upregulated in PCa compared to normal tissue and it acted as an oncogene in some previous studies [25–28]. However, the mechanisms of miR-96-5p as a tumor promoter in PCa have not been fully elucidated. The NF-kB pathway has been studied for many years and its significant role in immunity, inflammation and other physiological processes has been fully confirmed. Previous studies showed that EMT was potently administrated by several signaling pathways, such as TGF-b, Wnt, and ErbB [29,30]. While accumulating studies have indicated that the NF-kB signaling pathway also played a crucial role in inducing and maintaining EMT in a variety of tumors [31–34]. Furthermore, some evidence has illustrated that activation of the NF-kB pathway was also related to the metastasis of PCa [16,35].
Materials and Methods
Study design
This research aimed at evaluating the prostate cancer migration and invasion by miR-96-5p-induced NDRG1 deficiency through regulation of the NF-kB signaling pathway, with a randomized clinical trial (registered at Iranian Registry of Clinical Trials, N22021073034422), which was conducted in the Molecular Genetic and Reproductive Biology Department, Kowsar poly-clinic, Tehran, Iran. The study was approved by the Ethics Committee of Kowsar polyclinic Research Institute and all participants signed informed written consent prior to the experiment whose prostate tissues were taken.
Clinical samples and cell lines
Twenty paired PCa and adjacent normal prostate tissue were collected during surgery at the Molecular Genetic and Reproductive Biology Department, Kowsar polyclinic, Tehran, Iran. RWPE-1, LNCaP, C4-2, PC3, and DU145 cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). RWPE-1 cells were grown in keratinocyte-SFM (Invitrogen, USA). LNCaP, C4-2, PC3, and DU145 were cultured in RPMI1640 medium containing 10% fetal bovine serum (FBS) and penicillin-streptomycin (100 U/mL) (Solarbio, Beijing, China). All cell lines were incubated under a humidified atmosphere at 37 °C with 5% CO2. This study has complied with the ARRIVE guidelines and was carried out in accordance with the U.K. Animals Act, 1986, EU Directive 2010/63/EU for animal experiments, as well as respecting the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978). Twelve replicates per each condition of the experiment were evaluated.
Western blot
After cleaning with cold PBS twice, the tissues or cells were collected, and then extracted the whole cell lysate with RIPA buffer (Solarbio, Beijing, China) concentration was measured by a detection kit (Solarbio, Beijing, China) according to the manufacturer’s guidance. The same amount of protein in each sample was placed in 10% gel by SDS-PAGE and then transferred to the nitrocellulose membrane. To block the membrane, 5% non-fat milk or 5% BSA (Solarbio, Beijing, China) was utilized, then incubated with primary antibodies anti-NDRG1, diluted 1: 10 000, Ki-67, diluted 1: 1 000, Abcam; p65, p-p65, IkBa, p-IkBa, diluted 1: 1 000, Cell Signaling Technology; E-cadherin, N-cadherin diluted 1: 1 000, GAPDH, diluted 1: 2 000, vimentin, diluted 1: 10 000 Proteintech). After incubation with the corresponding secondary peroxidase-conjugated antibody, the protein bands were displayed with chemiluminescence dissolvent (Solarbio, Beijing, China).
Quantitative real-time polymerase chain reaction (qRT-PCR) analysis
Total RNA was extracted by utilizing TRIzol reagent (Invitrogen, USA) following the manufacturer’s guidance. Then 5 μg total RNA was transcribed to cDNA according to the protocol supplied with the HiFiScript cDNA Synthesis Kit (Cwbio, Taizhou, China). The mRNA expression was measured by SYBR Green qPCR master mix. The expression levels of all mRNA were normalized to GAPDH or U6. GAPDH is constitutively expressed in almost all tissues in high amounts. For this reason, GAPDH has been chosen as a control for protein normalization. All assays were conducted three times independently. The primers for qRT-PCR were listed as followed:
NDRG1 forward: 5’-GTCCTTATCAACGTGAACCCTT-3’
NDRG1 reverse: 5’-GCATTGGTCGCTCAATCTCCA-3’
GAPDH forward: 5’-GCTCTCTGCTCCTCCTGTTC-3’
GAPDH reverse: 5’-ACGACCAAATCCGTTGACTC-3’
miR-96-5p forward: 5’-CCTCGATTTGGCACTAGCAC-3’
miR-96-5p reverse: 5’-TATGGTTGTTCTGCTCTCTGTCTC-3’
U6 forward: 5’-CGCTTCGGCAGCATATAC-3’
U6 reverse: 5’-TTCACGAATTTGCGTGTCATC-3’
Immunofluorescence
Each group of cells was seeded on 24- -well plates using glass coverslips (Beijing Solarbio, China), fixed with 4% paraformaldehyde, and infiltrated with 0.5% Triton X-100. Then, 5% BSA was used to block cells for 1 hour and incubated with the primary antibody. NDRG1, (diluted 1: 200, Abcam), p-P65 (diluted 1: 1 600, CST) at 4°C overnight, followed by incubation with FITC-labeled or TRITC-labeled secondary antibody (diluted 1: 200, Proteintech, China) for 2 hours. Finally, the cells were stained with DAPI, and the images were detected under a confocal microscope (FV500; Olympus).
Immunohistochemical analysis
Tissue microarray was purchased from Alenabio, Xi’an (PR803d). The six tissues with lymph node metastasis were also collected from the Molecular Genetic and Reproductive Biology Department, Kowsar poly-clinic, Tehran, Iran. Standard immunohistochemistry (IHC) protocols were applied with specific antibodies following previously reported [36].
Luciferase reporter assay
The luciferase reporter assay was conducted with the Dual-Luciferase Reporter Assay kit (Promega, USA) pmirGLO; pmirGLO-WT and pmirGLO-MUT for NDRG1-3’UTR were cotransfected into 293T cell lines, together with miR-96-5p or miR-183-5p mimics, by using Lipoferctamine™ 2000 (Invitrogen, USA). After transfection in 48 hours, Renilla luciferase activity acts as a standard of the relative luciferase activity. Three independent assays were performed.
Cell transfection
The cells were transfected with the control, siRNA, miRNA mimics/inhibitors were purchased from GenePharma (Shanghai, China) using LipofectamineTM 2000 (Thermo Fisher, USA) following the manufacturer’s guidance. siRNAs for NDRG1 were defined as siNDRG1#1 and siNDRG1#2, siNDRG1#3, respectively. All siRNA are listed as follow- ed: si1: NDRG1-homo-688, si2: NDRG1-homo-835, and si3: NDRG1-homo-956. To overexpress NDRG1, full-length NDRG1 was cloned into a modified LV18 lentiviral vector (GenePharma, Shanghai, China), while an empty vector served as a control and was screened with puromycin. Luciferase express LV11 lentiviral vector (GenePharma, Shanghai, China) was transfected and screened with neomycin scratch assay. LNCaP, C4-2, PC3, and DU145 cells were added into 6-well plates with a density of 6×105 cells per well. When the cells are fully attached, the 2- mm scratch will divide the well into three equal parts. Next, the cells were cultured in a serum-free medium for 48 hours. The cells were detected and photographed at 0, 24 and 48 hours, respectively. The scratch healing rate was calculated by ImageJ software.
Migration and invasion assays
Cell migration and invasion abilities were identified by transwell chambers which consist of an 8-mm membrane filter covered with or without Matrigel (BD Biosciences). The cells were cultured with serum-free medium for 24 hours before use. The cells (1–2×105) in serum-free medium were seeded to the upper chambers. Lower chambers were supplied with a medium containing 10% FBS. After incubation for 24–48 hours, the cells at the bottom of the chamber were fixed with 4% paraformaldehyde, infiltrated with 0.5% Triton X-100, stained with DAPI, and counted by a fluorescence microscope.
Animal experiment
Animal experiments have been approved by the Ethics Committee of the medical supervisory team, Molecular Genetic and Reproductive Biology Department, Kowsar poly-clinic, Tehran, Iran. This study has complied with the ARRIVE guidelines and was carried out in accordance with the U.K. Animals Act, 1986, EU Directive 2010/63/EU for animal experiments, as well as respecting the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978). BALB/c nude male mice (5–6 weeks old) were raised in a room under sterile conditions. The DU145 cells with high expression of NDRG1 were directly subcutaneously injected to establish the model of subcutaneous xenograft (N = 5 mice/group, 3.0×106 cells / 100 μL). The cells were added to Matrigel (BD Biosciences) with a culture medium (1: 1 diluted). D-luciferin/D-PBS at a concentration of 15 mg/mL was given through intraperitoneal injections with 10 μL/g for imaging after 6 weeks of feeding and then all primary tumors were carried out. The two mice with suspected metastatic foci were kept feeding for 8 weeks. Primary tumors and suspected metastatic foci were excised, embedded, and fixed. Hematoxylin & eosin staining and immunohistochemistry analyses were conducted.
Statistical analysis
SPSS v.21.0 software (USA) and GraphPad Prism Software 7.0 (USA) were used for data assessment. Mean ± SD was used to show experimental results. Student’s t-test or one-way ANOVA was used to reveal the differences between the groups. P-values < 0.05 were considered statistically significant.
Results
NDRG1 expression is decreased in PCa and affected the prognosis of patients. To investigate the clinical significance of NDRG1 in PCa, the mRNA sequencing dataset of PCa from the Oncomine database [37] was evaluated. The dataset showed that NDRG1 expression was decreased in PCa compared with the normal tissues and showed a declined trend with Gleason score increase (Fig. 1A, B). The expression of NDRG1 was also downregulated in mRNA and protein levels in PCa cells (DU145, LNCaP, C4-2, PC3) compared with normal prostate epithelial cells (RWPE-1) (Fig. 1C, D). Most of the proteins are located in the cytoplasm (Fig. 1E). Our study further measured the expression levels of NDRG1 in 20 paired PCa patients and an 80-point tissue chip combined with six metastatic specimens. The NDRG1 expression level in PCa was also decreased. There was a tendency for a gradual decrease of NDRG1 level in normal tissue, benign prostatic hyperplasia tissue, localized PCa, and metastatic PCa tissue judged by immunohistochemistry (Fig. 1F–H). Furthermore, the patients with a high level of NDRG1 had higher overall survival than the low according to the dates from GSE16560 (N = 281) [38].
NDRG1 suppresses EMT, migration, and invasion in PCa cells
To determine the function of NDRG1 in human PCa cells, we transfected lentivirus to overexpress NDRG1 in two cell lines (LNCaP, DU145) with relatively low expression of NDRG1 (Fig. 2A) and siRNA to silenced NDRG1 in relatively high expression of NDRG1 cell lines (C4-2, PC3). To achieve a better-silenced effect, we selected three siRNA to identify in two cell lines (Fig. 3A). The C42 and PC3 were knocked out with siRNA1 and siRNA2, respectively. Relative to control cells, NDRG1-overexpressing cells significantly inhibited migration and NDRG1 knockdown cells significantly promoted migration in the scratch assay (Fig 2. C, D, 3C, D). Transwell assays were also performed and the result indicated a consistent trend in migration. The overexpression group showed a strong ability to inhibit invasion and the knocking-down group showed a high ability to promote invasion, especially in the PC3 cell line (Fig. 2E, F, 3E, F). Furthermore, western blot analysis implicated that upregulating NDRG1 increased the expression of E-cadherin and decreased vimentin and N-cadherin in LNCaP and DU145 cells (Fig. 2B). Conversely, silencing NDRG1 had an opposite effect on these EMT markers (Fig. 3B). These results demonstrate that NDRG1 suppresses migration, invasion, and EMT in PCa cells in vitro. MiR-96-5p expression is increased in PCa and promotes EMT in PCa cells. The miR-96-5p expression was analyzed by miRNA sequencing dataset of PCa from The Cancer Genome Atlas (TCGA) [39]. The data suggested that miR-96-5p was significantly upregulated in PCa compared with adjacent normal tissues (Fig. 4A). We further investigated the expression levels of miR-96-5p in different cell lines. Compared with the RWPE1 cell line, the expression of miR-96-5p was significantly increased (Fig. 4B). In the tumor tissues, we found the same trend (Fig. 4C). Then, transfection of PC3 cells was performed with mimic and inhibitor of miR-96-5p. The wound-healing assays revealed that overexpression or knocking down of miR-96-5p can promote or inhibit migration, respectively (Fig. 4D). Transwell assays further confirmed that miR-96-5p could promote migration and invasion of PCa (Fig. 4E). NDRG1 is directly targeted by miR-96-5p, and NDRG1 is important for miR-96-5p-mediated EMT. Our previous study found that miR- -182-5p could target the expression of NDRG1 [40]. Further exploration of the possible mechanism that contributed to NDRG1 downregulation in PCa, we used bioinformatics databases TargetScanHuman 7.2 to predict potential miRNA targets in NDRG1 mRNA [41]. Interestingly, we found miR-96-5p and miR-183-5p may both have the opportunity to combine with NDRG1 mRNA 3’-UTR binding sites. Moreover, miR-183~96~182 as a cluster had been considered to play a significant role in tumor cell survival, proliferation, and migration. Further sequence analysis indicated the presence of only one putative binding site for miR-96-5p and miR-183-5p in the NDRG1 3’-UTR. Luciferase assay was carried out to detect the changes of miR-96-5p (Fig. 5B) and miR-183-5p transiently transfected with WT NDRG1 3’-UTR and mutated NDRG1 3’-UTR in 293T cells. As shown in Fig. 2, luciferase activity was remarkably repressed only in WT NDRG1 3’-UTR. While there was no significant change in fluorescence value when mutated NDRG1 3’-UTR co-transfected with miR-96-5p in 293T cells. Further verification of the regulatory relationship, western blot was conducted in different treatment groups in PC3 cells. Fig. 5C showed that miR-96-5p inhibitor could upregulate NDRG1 expression while miR-96-5p mimics downregulate NDRG1 expression. Moreover, Spearman’s correlation analysis of the TCGA database demonstrated that miR-96-5p mRNA level was negatively correlated with NDRG1 mRNA level in PCa tissues (r = −0.192, P < 0.001; Fig. 5D) by using the star base database. Clinical samples also demonstrated that the expression of mRNA levels was negatively correlated with each other (r2 = 0.397, P < 0.01; Fig. 5E). There were significant differences in the ability of migration and invasion between the control group and the group transfected with miR-96-5p inhibitor or siNDRG1 in PC3 cells (Fig. 5F, G). Western blot indicating protein changes also illustrated that NDRG1 was crucial to miR-96-5p mediated EMT (Fig. 5F, G).
Downregulating NDRG1 activates the NF-κB signaling pathway promoting EMT in PCa cells
To further assess the mechanism of NDRG1 promoting the metastasis of PCa, the next generation sequence was used to compare overexpressed NDRG1 cells in DU145 with normal cells (Fig. 6A). By comparing the go enrichment analysis of downstream pathway changes, we found that the PI3K-AKT pathway has been significantly modified (Fig. 6B). It has been confirmed that NF- kB could be activated as a downstream pathway of pAKT in many pieces of research. So, we further explored the relationship between NDRG1 and NF-kB pathway. We analyzed the subcellular localization of phosphorylated p65 (p-p65) in PC3 and C4-2 cells using immunofluorescence. Knocking down the expression of NDRG1 could increase the number of p-p65 and promote its nuclear translocation (Fig. 6C). Western blot also demonstrated that downregulating NDRG1 increased the expression of p-p65 and phosphorylated IkBa (p-IkBa) in C4-2 and PC3 cells (Fig.6D). To further verify whether NDRG1 can mediate EMT through the NF-kB pathway, we added pyrrolidinedithiocarbamate ammonium (PDTC) with 1.0 ng/mL, an inhibitor of NF-kB pathway. When PDTC was added in PC3 cells, the content of p-p65 and p-IkBa was induced as well as the expression of vimentin and N-cadherin. However, there was an increased level of p-p65 and p-IkBa when downregulating NDRG1. Moreover, inhibition of NF-kB signaling by PTDC impaired the stimulatory effect of NDRG1 down-expression on EMT in PCa cells (Fig. 6E, F). The above data indicate that downregulating NDRG1 activates the NF-kB signaling pathway promoting EMT in PCa cells.
Elevating NDRG1 inhibits PCa metastasis in vivo
To determine the function of NDRG1 on the metastasis of PCa in vivo, we used lentivirus to overexpress NDRG1 in luciferase-labeled vector DU145 cells and established the xenograft model by directly subcutaneous injection of tumor cells into nude mice. As shown in Fig. 7A, compared with the control group, the metastatic ability of the overexpression group was lower. After feeding for 6 weeks, there were two mice in the control group had distant metastases, while no suspicious lesions were found in the treatment group under the imaging system. We also discovered that the tumor volume and weight were significant differences between the two groups. Upregulating NDRG1 inhibited tumor proliferation at the same time (Fig. 7B–D). Hematoxylin & eosin staining showed the tumor in situ and one typical distant metastasis lesion near the spine. The red arrow indicated the metastatic tumor area (Fig. 7E). Furthermore, the immunohistochemistry of tumor tissue and western blot demonstrated that upregulating NDRG1 dramatically reduced the level of Ki-67 and vimentin, while increasing E-cadherin (Fig. 7F, G). Consequently, these findings demonstrate that elevating NDRG1 inhibits PCa proliferation and metastasis in vivo.
Discussion
The main findings of our study display novel insights that miR-96-5p induced NDRG1 deficiency and activated NF-kB signal pathway, which further promoted the EMT of PCa. Here, we observed that NDRG1 expression was decreased in PCa tissues, and high expression of miR- -96-5p correlated with PCa cell migration and invasion. Our results further indicated that miR-96-5p via directly targeting NDRG1 promoted EMT in PCa cells, leading to the development of PCa metastasis. Therefore, our study uncovered novel insights that miR-96-5p promotes EMT through NDRG1 and NF-kB signal pathways, elucidating the tumor suppressor gene of NDRG1 and the oncogenic function of miR-96-5p in PCa. The role of NDRG1 in inhibiting the progression of metastasis has been described in different cancer research [42–44]. Other studies also partly elucidated the mechanism of decreased levels of NDRG1 in PCa and its possible ways of regulating expression [36,40]. In fact, available evidence has indicated that NDRG1 might act as a tumor suppressor in several PCa cell lines through different molecular mechanisms [9,11]. However, the mechanism of NDRG1 regulating migration and invasion is still partly unknown. In our study, we illustrated that inhibiting the activation of the NF-kB pathway could change the EMT markers induced by NDRG1 depletion, and miR-96-5p inhibitors overexpression also reversed the effect of NDRG1 downregulation to the EMT markers. We also demonstrated that overexpression of NDRG1 inhibited the proliferation and metastasis of PCa in vivo. Higher miR-96-5p expression was also accompanied by lower NDRG1 expression in PCa tissues, which further illustrates the negative relation between the two molecules in PCa progression. More importantly, these demonstrate that miR-96-5p regulates NDRG1 expression and NDRG1 regulates EMT by modulating NF-kB activation, in part, state that NDRG1 suppressive function in cell migration, invasion, and EMT mediate by miR-96-5p and NF-kB. MiR-183 cluster is a significant gene located on the short arm of chromosome 7 (7q32.2). Three mature miRNAs (miR-96, -182, and -183) were generated from a single polycistronic transcript. The expression of the miR-183 cluster has been documented in several cancers. Most studies assumed that the miR-183 cluster has shown an oncogenic function in cancers, while some have suggested inhibition of these effects [43]. Other studies have illustrated that miR-182-5p induced NDRG1 deficiency and promoted proliferation and metastasis in PCa cells [40]. In this study, we further explored the effect of miR-96-5p and miR-183-5p on NDRG1. Luciferase activity was remarkably repressed only in miR-96-5p. Several previous studies have suggested that miR-96-5p was upregulated in different kinds of tumors and a high level of miR--96-5p promoted cancer cell migration and invasion via different mechanisms and also predicted poor survival. Siu et al. illustrated that miR-96-5p could target the tumor suppressor ETV6, downregulated EMT markers’ expression in PCa [27]. Moreover, TGF-b could regulate the expression of miR-96 through Smad-dependent transcription. MiR-96 also promoted bone metastasis in PCa [26]. Notably, a study by Long et al. showed that miR-96 controlled the AR signaling pathway and promoted PCa progression by adjusting the RARg network [42,43]. In our study, these findings reveal that miR-96-5p is elevated in PCa and promoted EMT by regulating NDRG1 expression to control NF-kB pathway activity. A large number of studies have illustrated that the NF-kB signal was significantly activated in several kinds of human tumors, which are closely associated with tumor progression and metastasis [31,42]. In glioma cancer, the activation of the NF-kB signal played a significant role in promoting cell migration and invasion [42,44]. In colorectal cancer, DCLK1 promoted EMT via the PI3K/Akt/NF-kB pathway [32]. In addition, a study by Mei et al. has demonstrated that the level of miR-145-5p was induced by inhibiting the Sp1/NF-kB pathway, which limited the migration and invasion of esophageal squamous cancer cells [33]. Accumulating evidence has illustrated that NF-kB signaling played a crucial role in promoting the invasion and metastasis of PCa [16]. Shang et al. showed that lncRNA-PCAT1 induced CRPC progression by positively regulating AKT/NF-kB signaling [32]. Notably, Zhang et al. discovered that migration and invasion enhancer 1 was an NF-kB induced gene, which enhanced the proliferation and invasion of human PCa cells [23]. In the present study, we revealed that miR-96-5p activates the NF-kB pathway by directly targeting NDRG1, which promotes EMT in PCa cells. Moreover, we also demonstrated that NF-kB signaling activity plays a significant role in the invasion and migration of PCa cells.
Conclusions
In summary, we demonstrate that NDRG1 loss is correlated with cell metastasis and poor prognosis of PCa patients. During the development of PCa, the abnormally high expression of miR-96-5p can promote this biological process, inhibit the expression of NDRG1, activate the NF-kB pathway, and promote cell EMT. Based on our findings, we propose a new molecular mechanism in which miR-96-5p promotes EMT by regulating NDRG1 expression to control NF-kB pathway activation in PCa. These findings provide a new understanding of the progression of PCa and further guide clinical practices.
Acknowledgments
This study was conducted at the Molecular Genetic and Reproductive Biology Department, Kowsar poly-clinic, Tehran, Iran, thus appreciating the spiritual support of this center is admitted.
Authors’ contributions
Aida Jamshidian and Hengameh Ghaffari Monfared, the corresponding authors of this article declare that all the mentioned individuals in this article are members of this research team and had substantial contributions to the conception and design, acquisition of data, analysis, and interpretation of data, drafting of the article, revising it, and final approval of the version to be published.
Availability of data and materials
The data used in this study are available from the corresponding author upon request.
Consent for publication
By submitting this document, the authors declare their consent for the final accepted version of the manuscript to be considered for publication.
Declaration of interest
The authors report no conflicts of interest in this work.
Zdroje
1. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (3): 209–249. doi: 10.3322/caac.21660.
2. Zhang K, Bangma CH, Roobol MJ. Prostate cancer screening in Europe and Asia. Asian J Urol 2017; 4 (2): 86–95. doi: 10.1016/j.ajur.2016.08.010.
3. Fang BA, Kovacevic Z, Park KC et al. Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy. Biochim Biophys Acta 2014; 1845 (1): 1–19. doi: 10.1016/ j.bbcan.2013.11.002.
4. Qu X, Zhai Y, Wei H et al. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem 2002; 229 (1–2): 35–44. doi: 10.1023/a: 1017934810825.
5. Nieto MA, Huang RY, Jackson RA et al. EMT: 2016. Cell 2016; 166 (1): 21–45. doi: 10.1016/j.cell.2016.06.028.
6. Thiery JP, Acloque H, Huang RYJ et al. Epithelial-mesenchymal transitions in development and disease. Cell 1999; 139 (5): 871–890. doi: 10.1016/j.cell.2009.11.007.
7. Liu W, Yue F, Zheng M et al. The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget 2015; 6 (11): 8851–8874. doi: 10.18632/oncotarget.3316.
8. Wangpu X, Lu J, Xi R et al. Targeting the metastasis suppressor, N-myc downstream regulated gene-1, with novel di-2-pyridylketone thiosemicarbazones: suppression of tumor cell migration and cell-collagen adhesion by inhibiting focal adhesion kinase/paxillin signaling. Mol Pharmacol 2016; 89 (5): 521–540. doi: 10.1124/mol.115.103044.
9. Jin R, Liu W, Menezes S et al. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of beta-catenin through mechanisms involving FRAT1 and PAK4. J Cell Sci 2014; 127 (14): 3116–3130. doi: 10.1242/jcs.147835.
10. Tu LC, Yan X, Hood L et al. Proteomics analysis of the interactome of N-myc downstream-regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Mol Cell Proteomics 2007; 6 (4): 575–588. doi: 10.1074/mcp.M600249-MCP200.
11. Xi R, Pun IH, Menezes SV et al. Novel thiosemicarbazones inhibit lysine-rich carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) coisolated (LYRIC) and the LYRIC-induced epithelial-mesenchymal transition via upregulation of N-myc downstream-regulated gene 1 (NDRG1). Mol Pharmacol 2017; 91 (5): 499–517. doi: 10.1124/mol.116.107870.
12. Lee JC, Chung LC, YJ Chen et al. N-myc downstream-regulated gene 1 downregulates cell proliferation, invasiveness, and tumorigenesis in human oral squamous cell carcinoma. Cancer Lett 2014; 355 (2): 242–252. doi: 10.1016/j.canlet.2014.08.035.
13. Hu ZY, Xie WB, Yang F et al. NDRG1 attenuates epithelial-mesenchymal transition of nasopharyngeal cancer cells via blocking Smad2 signaling. Biochim Biophys Acta 2015; 1852 (9): 1876–1886. doi: 10.1016/j.bbadis.2015.06.009.
14. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136 (2): 215–233. doi: 10.1016/j.cell.2009.01.002.
15. Li J, Ye D, Shen P et al. Mir-20a-5p induced WTX deficiency promotes gastric cancer progressions through regulating PI3K/AKT signaling pathway. J Exp Clin Cancer Res 2020; 39 (1): 212. doi: 10.1186/s13046-020-01718-4.
16. Ren D, Yang Q, Dai Y et al. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-kappaB signaling pathway. Mol Cancer 2017; 16 (1): 117. doi: 10.1186/s12943-017-0688-6.
17. Anderson O, Guttilla Reed IK. Regulation of cell growth and migration by miR-96 and miR-183 in a breast cancer model of epithelial-mesenchymal transition. PLoS One 2020; 15 (5): e0233187. doi: 10.1371/journal.pone.0233187.
18. Huang X, Lv W, Zhang JH et al. MiR96 functions as a tumor suppressor gene by targeting NUAK1 in pancreatic cancer. Int J Mol Med 2014; 34 (6): 1599–1605. doi: 10.3892/ijmm.2014.1940.
19. Liu ZM, Wu ZY, Li WH et al. MiR-96-5p promotes the proliferation, invasion, and metastasis f papillary thyroid carcinoma through down-regulating CCDC67. Eur Rev Med Pharmacol Sci 2019; 23 (8): 3421–3430. doi: 10.26355/eurrev_201904_17706.
20. Ress AL, Stiegelbauer V, Winter E et al. MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients. Mol Carcinog 2015; 54 (11): 1442–1450. doi: 10.1002/mc.22218.
21. Yao Q, Pei Y, Zhang X et al. MicroRNA-96 acts as a tumor suppressor gene in human osteosarcoma via target regulation of EZRIN. Life Sci 2018; 203: 1–11. doi: 10.1016/j.lfs.2018.04.012.
22. He C, Zhang Q, Gu R et al. MiR-96 regulates migration and invasion of bladder cancer through epithelial-mesenchymal transition in response to transforming growth factor-beta1. J Cell Biochem 2018; 119 (9): 7807–7817. doi: 10.1002/jcb.27172.
23. Wang H, Ma N, Li W et al. MicroRNA-96-5p promotes proliferation, invasion and EMT of oral carcinoma cells by directly targeting FOXF2. Biol Open 2020; 9 (3): bio049478. doi: 10.1242/bio.049478.
24. Wei S, Zheng Y, Jiang Y et al. The circRNA circPTPRA suppresses epithelial-mesenchymal transitioning and metastasis of NSCLC cells by sponging miR-96-5p. EBioMedicine 2019; 44: 182–193. doi: 10.1016/j.ebiom.2019.05.032.
25. Pudova EA, Krasnov GS, Nyushko KM et al. MiRNAs expression signature potentially associated with lymphatic dissemination in locally advanced prostate cancer. BMC Med Genomics 2020; 13 (Suppl 8): 129. doi: 10.1186/s12920-020-00788-e9.
26. Siu MK, Tsai YC, Chang YS et al. Transforming growth factor-beta promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway. Oncogene 2015; 34 (36): 4767–4776. doi: 10.1038/onc.2014.414.
27. Tsai YC, Chen WY, Siu MK et al. Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6. Cancer Lett 2017; 384: 1–8. doi: 10.1016/j.canlet.2016.10.014.
28. Voss G, Haflidadottir BS, Jaremo H et al. Regulation of cell-cell adhesion in prostate cancer cells by microRNA-96 through upregulation of E-Cadherin and EpCAM. Carcinogenesis 2020; 41 (7): 865–874. doi: 10.1093/carcin/bgz191.
29. Miettinen PJ, Ebner R, Lopez AR et al. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994; 127 (6 Pt 2): 2021–2036. doi: 10.1083/jcb.127.6.2021.
30. Wang M, Ren D, Guo W et al. N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell--like traits via ErbB signaling in prostate cancer cells. Int J Oncol 2016; 48 (2): 595–606. doi: 10.3892/ijo.2015.3270.
31. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 2013; 12: 86. doi: 10.1186/1476-4598-12-86.
32. Liu W, Wang S, Sun Q et al. DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-kappaB pathway in colorectal cancer. Int J Cancer 2018; 142 (10): 2068–2079. doi: 10.1002/ijc.31232.
33. Mei LL, Wang WJ, Qiu YT et al. MiR-145-5p suppresses tumor cell migration, invasion, and epithelial to mesenchymal transition by regulating the Sp1/NF-kappaB signaling pathway in esophageal squamous cell carcinoma. Int J Mol Sci 2017; 18 (9): 1833. doi: 10.3390/ijms180 91833.
34. Wang J, Tian L, Khan MN et al. Ginsenoside Rg3 sensitize hypoxic lung cancer cells to cisplatin via the blocking of NF-kappaB mediated epithelial-mesenchymal transition and stemness. Cancer Lett 2018; 415: 73–85. doi: 10.1016/j.canlet.2017.11.037.
35. Zhang J, Kuang Y, Wang Y et al. Notch-4 silencing inhibits prostate cancer growth and EMT via the NF-kappaB pathway. Apoptosis 2017; 22 (6): 877–884. doi: 10.1007/s10495-017-1368-0.
36. Li Y, Pan P, Qiao P et al. Downregulation of N-myc downstream-regulated gene1 caused by the methylation of CpG islands of NDRG1 promoter promotes proliferation and invasion of prostate cancer cells. Int J Oncol 2015; 47 (3): 1001–1008. doi: 10.3892/ijo.2015. 3086.
37. Oncomine Solution for Next-Generation Sequencing. [online]. Available from: https: //www.oncomine.com/
38. Find more NCBI PubMed artoicles. [online]. Available from: https: //www.genomenon.com/mastermind-lp-gads-ncbi-search/?gad_source=1&gclid=Cj0KCQjwq86wBhDiARIsAJhuphnPBfH4VPcdKhN3WeYSBB_e3Qv0QTZVqyzyBROks11l4SHktBX9ZqAaAicbEALw_wcB.
39. NIH National Cancer Institute. [online]. Available from: https: //www.cancer.gov/
40. Liu R, Li J, Teng Z et al. Overexpressed microRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream-regulated gene 1 (NDRG1). PLoS One 2013; 8 (7): e68982. doi: 10.1371/journal.pone.0068982.
41. http: //www.targetscan.org.
42. Bandyopadhyay S, Pai SK, Hirota S et al. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene 2004; 23 (33): 5675–5681. doi: 10.1038/sj.onc.1207734.
43. Matsugaki T, Zenmyo M, Hiraoka K et al. N-myc downstream-regulated gene 1/Cap43 expression promotes cell differentiation of human osteosarcoma cells. Oncol Rep 2010; 24 (3): 721–725. doi: 10.3892/or_00000913.
44. Mi L, Zhu F, Yang X et al. The metastatic suppressor NDRG1 inhibits EMT, migration and invasion through interaction and promotion of caveolin-1 ubiquitylation in human colorectal cancer cells. Oncogene 2017; 36 (30): 4323–4335. doi: 10.1038/onc.2017.74.
Štítky
Detská onkológia Chirurgia všeobecná OnkológiaČlánok vyšiel v časopise
Klinická onkologie
2024 Číslo 2
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- Fixní kombinace paracetamol/kodein nabízí synergické analgetické účinky
- Tramadol a paracetamol v tlumení poextrakční bolesti
- Antidepresivní efekt kombinovaného analgetika tramadolu s paracetamolem
Najčítanejšie v tomto čísle
- Význam aberantní metylace DNA pro diagnostiku a terapii nádorových onemocnění
- Faktory ovplyvňujúce prežívanie pacientov a vývoj GvHD po alogénnej transplantácii krvotvorných buniek od HLA-identických súrodencov – skúsenosť jedného centra
- Carcinoid syndrome with right-sided valve involvement – a case report and review of the literature
- Možnosti zavedení časné nádorové regrese jako potenciálního prediktivního markeru do každodenní klinické praxe u pacientů s metastatickým kolorektálním karcinomem RAS divokého typu léčených cetuximabem – neintervenční observační studie